share_log

RBC Capital Reiterates Outperform on Bicycle Therapeutics, Maintains $35 Price Target

RBC Capital Reiterates Outperform on Bicycle Therapeutics, Maintains $35 Price Target

RBC Capital重申对bicycle therapeutics的表现优异评级,维持35美元的目标股价。
Benzinga ·  2024/11/02 01:51  · 评级/大行评级

RBC Capital analyst Gregory Renza reiterates Bicycle Therapeutics (NASDAQ:BCYC) with a Outperform and maintains $35 price target.

RBC Capital的分析师Gregory Renza重申Bicycle Therapeutics(纳斯达克:BCYC)为Outperform,并维持35美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发